For my part I don't have an agenda (other than to promote deeper understanding) and was not trying to "discredit" the Grimm review paper per-se. To the contrary, I think it is very interesting and compelling insofar as showing that BT can provide excellent outcomes. I was, however, questioning whether the surgical outcomes considered were representative of the best surgical care available.
For low risk patients there were only six surgical studies considered. Looking at the two of these papers that are freely available reveals the following:
Nguyen et al: overall positive surgical margin rate = 23% for cohort that was 72% pT2 / 28% pT3
Kane et al: positive surgical margin rate = 35% all D’Amico low-risk
These psm rates are mediocre to poor so it does not seem surprising that the corresponding rates of biochemical relapse were also mediocre to poor, since it is well known that biochemical relapse correlates strongly with surgical margin status.
Although many surgical margin rates and biochemical relapse rates superior to this have been published, they apparently were not considered because they did not include stratification by pre-op risk criteria (e.g. c-stage), which just happens to be less natural for inclusion in a paper on surgery.
Given this, I think the takeaway regarding surgery compared to BT should not be that BT is necessarily superior but, rather, that the skill and track record of surgeon is paramount in order to achieve outcomes comparable (or potentially even superior) to those shown for BT.
Post Edited (njs) : 6/23/2013 12:51:55 PM (GMT-6)